Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
7
South Korean military plans to launch new division for future warfare
-
8
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Teen smoking, drinking decline, while mental health, dietary habits worsen
[DISCLOSURE] Daewha Pharmaceutical (067080) reported on Oct. 12 that it has inked a US$20.12 million five-year contract with NovoSci in United Arab Emirates to supply pharmaceutical products under the condition its products are granted approval for sale in 11 countries including Saudi Arabia.
This amounts to 16.16 percent of its revenue last year.
By Yun Jeong-hyeon (clareyun@heraldcorp.com)
This amounts to 16.16 percent of its revenue last year.
By Yun Jeong-hyeon (clareyun@heraldcorp.com)
